 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C9H14N2O |
| Molar mass | 166.224 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
ABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects,[1][2][3][4][5] and has been researched for treatment of both Alzheimer's disease[6] and ADHD.[7][8][9] It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α4β2, α7/5-HT3, and α2β2 nicotinic acetylcholine receptors but not α3β4 receptors[10][11][12] ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.[13]
YouTube Encyclopedic
-
1/5Views:1 797 4425559 584420780
-
Amaziing And Interesting Facts About Turkey | Studio One
-
Saturday Morning Physics - Oliver Kripfgans
-
Evolution of Genome Instability in Cancer with Don Cleveland - Sanford Stem Cell Symposium
-
Waters Upton Wanderings: The Evolution of a One-Place Study
-
Codex Humanus Das Buch der Menschlichkeit. Hörbuch Doku Teil 2
Transcription
See also
References
- ^ Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, et al. (July 1994). "(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization". The Journal of Pharmacology and Experimental Therapeutics. 270 (1): 310–318. PMID 7518514.
- ^ Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, et al. (July 1994). "(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization". The Journal of Pharmacology and Experimental Therapeutics. 270 (1): 319–328. PMID 7913497.
- ^ Brioni JD, O'Neill AB, Kim DJ, Buckley MJ, Decker MW, Arneric SP (October 1994). "Anxiolytic-like effects of the novel cholinergic channel activator ABT-418". The Journal of Pharmacology and Experimental Therapeutics. 271 (1): 353–361. PMID 7965735.
- ^ Prendergast MA, Terry AV, Jackson WJ, Marsh KC, Decker MW, Arneric SP, Buccafusco JJ (April 1997). "Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418". Psychopharmacology. 130 (3): 276–284. doi:10.1007/s002130050240. PMID 9151363. S2CID 34377165.
- ^ Dallanoce C, Magrone P, Matera C, Lo Presti L, De Amici M, Riganti L, et al. (December 2010). "Synthesis of novel chiral Δ2-isoxazoline derivatives related to ABT-418 and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes". European Journal of Medicinal Chemistry. 45 (12): 5594–5601. doi:10.1016/j.ejmech.2010.09.009. PMID 20932609.
- ^ Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA (March 1999). "Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease". Psychopharmacology. 142 (4): 334–342. doi:10.1007/s002130050897. PMID 10229057. S2CID 27337634.
- ^ Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, et al. (December 1999). "A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder". The American Journal of Psychiatry. 156 (12): 1931–1937. doi:10.1176/ajp.156.12.1931. PMID 10588407. S2CID 20375475.
- ^ Horrigan JP (April 2001). "Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder". Expert Opinion on Pharmacotherapy. 2 (4): 573–586. doi:10.1517/14656566.2.4.573. PMID 11336608. S2CID 41914443.
- ^ Spencer T, Biederman J (2002). "Non-stimulant treatment for Attention-Deficit/Hyperactivity Disorder". Journal of Attention Disorders. 6 (Suppl 1): S109–S119. doi:10.1177/070674370200601s13. PMID 12685525. S2CID 26801069.
- ^ Papke RL, Thinschmidt JS, Moulton BA, Meyer EM, Poirier A (February 1997). "Activation and inhibition of rat neuronal nicotinic receptors by ABT-418". British Journal of Pharmacology. 120 (3): 429–438. doi:10.1038/sj.bjp.0700930. PMC 1564486. PMID 9031746.
- ^ Dallanoce C, Magrone P, Matera C, Lo Presti L, De Amici M, Riganti L, et al. (December 2010). "Synthesis of novel chiral Δ2-isoxazoline derivatives related to ABT-418 and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes". European Journal of Medicinal Chemistry. 45 (12): 5594–5601. doi:10.1016/j.ejmech.2010.09.009. PMID 20932609.
- ^ Briggs CA, McKenna DG, Piattoni-Kaplan M (June 1995). "Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands". Neuropharmacology. 34 (6): 583–590. doi:10.1016/0028-3908(95)00028-5. PMID 7566493. S2CID 54338489.
- ^ Wilens TE, Decker MW (October 2007). "Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition". Biochemical Pharmacology. 74 (8): 1212–1223. doi:10.1016/j.bcp.2007.07.002. PMC 2974320. PMID 17689498.
 | This article about an anxiolytic is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 9 February 2024, at 06:13